The FDA reorganisation is being linked with the efforts of regulators elsewhere, such as in Europe and Japan, so that the approval process for new therapies can be streamlined without threatening patient safety.
Streamlining the approval process in order to meet growing demand will help the flow of investment into companies like Mesoblast.
They have been put through the ringer but they have substantial data being a global leader in their field.
The minutes will be interesting and I believe compelling. The consolidation and support is great to see for all LT holders.
GLTA
SD
Mesoblast stock(rock)-take March 2024, page-60
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
0.000(0.00%) |
Mkt cap ! $1.244B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.12 | $1.08 | $876.8K | 795.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 212919 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 23359 | 5 |
View Market Depth
| Last trade - 10.23am 18/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.08 |
Change
0.000 ( 0.53 %) |
||||
| Open | High | Low | Volume | ||
| $1.10 | $1.12 | $1.08 | 141178 | ||
| Last updated 10.43am 18/06/2024 ? | |||||
| MSB (ASX) Chart |
